Downloads / CME Credit

Course Director & Faculty

Jeffrey E. Lancet, MD
Co-Chair and Presenter
Jeffrey E. Lancet, MD
Moffitt Cancer Center
Tampa, Florida
Robert J. Soiffer, MD
Co-Chair and Presenter
Robert J. Soiffer, MD
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts


Gaylord Palms Convention Center
Florida Hall E
6000 West Osceola Parkway
Kissimmee, FL 34746


12:30 PM Welcome and Introduction: HCT and Novel Therapy in AML—What Are the Implications?
● Introductory comments on how emerging therapies may be used in transplant-eligible patients with AML—and what their emergence will mean for post-HCT outcomes (Jeffrey Lancet, MD)

12:40 PM HCT in AML and the Impact of Novel Therapies
● A look at the key evidence on novel cytotoxic and targeted therapies in transplant-eligible populations with AML, and what impact their use will have on patient outcomes post-transplant (Jeffrey Lancet, MD)

1:00 PM Optimizing Post-HCT Outcomes in AML: What Can Clinicians Do?
● Expert insight on major post-transplant complications in AML—and what clinicians can do to recognize and manage these important issues to optimize post-HCT outcomes (Robert Soiffer, MD)

1:20 PM Thoughts on the Changing Role of HCT in AML and Audience Q&A
● Take-home points from the panel followed by audience Q&A session on the role of transplant in AML and the implications of emerging therapeutics for HCT-eligible patients (Jeffrey Lancet, MD, and Robert Soiffer, MD)

CME Information

Three Key Reasons to Attend

Activity Description & Educational Objectives

Hematopoietic stem cell transplant (HCT) clearly has a role in acute myeloid leukemia (AML) management, but one intriguing question on the future of HCT in AML concerns the rapid emergence of several novel and active therapeutic options for AML. Newer therapies, including novel cytotoxics and targeted agents, may offer patients who struggle to benefit from conventional chemotherapy a chance for better outcomes, including in high-risk settings or in populations where the benefit of “7+3” is uneven at best. What will the validation of newer therapies mean for HCT-eligible patients with AML and for post-HCT outcomes? At PeerView’s upcoming live event being held at the BMT Tandem Meetings in 2017, our panel of experts will address this important question and offer clinical insight and new evidence that may define how HCT is used in conjunction with a range of next-generation therapies in the AML setting.

Upon completion of this activity, participants should be better able to:

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, oncology transplant specialists, and other clinicians involved in the management of patients with acute myeloid leukemia.

Requirements for Successful Completion

In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon completion of the request for credit at the end of the post-test and evaluation form.

Media: Symposium
Release and Expiration Date: February 24, 2017
Time to Complete: 60 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chair and Presenters

Jeffrey E. Lancet, MD
Senior Member
Department Chair - Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Robert J. Soiffer, MD
Vice Chair, Department of Medical Oncology
Chief, Division of Hematologic Malignancies
Co-Chief, Stem Cell Transplantation
Institute Physician
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.


This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Please visit our other symposia on HL,, Fungal Infections,, Myelofibrosis,, and on Myeloma